| Drug Name |
Siltuximab |
| Drug ID |
BADD_D02021 |
| Description |
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks. |
| Indications and Usage |
Siltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive. |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AC11 |
| DrugBank ID |
DB09036
|
| KEGG ID |
D09669
|
| MeSH ID |
C504234
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
73090-421; 73090-420 |
| UNII |
T4H8FMA7IM
|
| Synonyms |
siltuximab | CLLB8 | cClB8 monoclonal antibody | Sylvant | CNTO-328 | monoclonal antibody CNTO-328 | CNTO 328 monoclonal antibody | monoclonal antibody CNTO 328 | monoclonal antibody CNTO328 |
